Skip to main content
. 2018 Oct 26;34(1):117–123. doi: 10.1080/14756366.2018.1532419

Figure 2.

Figure 2.

SLC-0111 increases cytotoxic effect of Doxorubicin in breast cancer cells. (a) Representative plots (lower) and relative quantification chart (upper) of Annexin V/PI assay of MCF7 treated for 48 h with either 90 nM Doxorubicin, or 100 µM SLC-0111, or the combination of the two. *p < 0.05, Two-way ANOVA, N = 3. (b) Quantification chart of Trypan Blue exclusion assay of MCF7 treated for 48 h with either 90 nM Doxorubicin, or 100 µM SLC-0111, or the combination of the two. ***p < 0.001 One-way ANOVA, N = 3. (c) Representative pictures (lower) and relative quantification chart (upper) of colony formation assay of MCF7 breast cancer cells treated for 14 days with either 10 nM Doxorubicin, or 100 µM SLC-0111, or the combination of the two. **p < 0.01, One-way ANOVA, N = 3.